Related Experiment Video
Updated: Jul 28, 2025

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
Targeting microbiome, drug metabolism, and drug delivery in oncology
Ai Sumiyoshi1, Hiroyuki Fujii2, Yusuke Okuma3
1Department of Pharmacy, National Cancer Center Hospital 5-1-1 Tsukiji Chuo, Tokyo 104-0045, Japan.
Abstract:
Recent emerging scientific evidence shows a relationship between gut microbiota (GM) and immunomodulation. In the recently published "Hallmarks of Cancer", the microbiome has been reported to play a crucial role in cancer research, and perspectives for its clinical implementation to improve the effectiveness of pharmacotherapy were explored. Several studies have shown that GM can affect the outcomes of pharmacotherapy in cancer, suggesting that GM may affect anti-tumor immunity. Thus, studies on GM that analyze big data using computer-based analytical methods are required. In order to successfully deliver GM to an environment conducive to the proliferation of immune cells both within and outside the tumor microenvironment (TME), it is crucial to address a variety of challenges associated with distinct delivery methods, specifically those pertaining to oral, endoscopic, and intravenous delivery. Clinical trials are in progress to evaluate the effects of targeting GM and whether it can enhance immunity or act on the TME, thereby to improve the clinical outcomes for cancer patients.
Insights
The gut microbiota (GM) influences cancer treatment effectiveness by modulating anti-tumor immunity. Research is exploring GM delivery methods and clinical trials to enhance cancer immunotherapy and patient outcomes.
Area of Science:
- Oncology
- Immunology
- Microbiome Research
Background:
- Emerging evidence links gut microbiota (GM) to immunomodulation.
- The microbiome plays a key role in cancer research and pharmacotherapy effectiveness.
- GM influences anti-tumor immunity and cancer treatment outcomes.
Purpose of the Study:
- To highlight the importance of studying gut microbiota in cancer.
- To explore challenges and perspectives for clinical implementation of GM modulation.
- To review GM's role in enhancing anti-tumor immunity and cancer pharmacotherapy.
Main Methods:
- Analysis of recent scientific evidence and published reports.
- Exploration of computer-based analytical methods for big data analysis of GM.
- Review of challenges in GM delivery methods (oral, endoscopic, intravenous).
Main Results:
- GM significantly impacts cancer pharmacotherapy outcomes.
- GM modulation holds potential for enhancing anti-tumor immunity.
- Targeting GM is being investigated in clinical trials for improved cancer patient outcomes.
Conclusions:
- Gut microbiota is a critical factor in cancer immunology and treatment.
- Further research and advanced analytical methods are needed to understand GM's role.
- Clinical trials are evaluating GM-based strategies to improve cancer immunotherapy and patient prognosis.
Related Concept Videos
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Microorganisms in Medicine and Therapeutics
Drug Biotransformation: Overview
Factors Influencing Bioavailability: First-Pass Elimination
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
The drug's acidity or basicity is essential in...

